aTyr Pharma, Inc. (ATYR)
NASDAQ: ATYR · Real-Time Price · USD
5.14
-0.25 (-4.64%)
At close: Jun 4, 2025, 4:00 PM
5.15
+0.01 (0.19%)
After-hours: Jun 4, 2025, 7:58 PM EDT
aTyr Pharma Revenue
In the year 2024, aTyr Pharma had annual revenue of $235.00K, down -33.43%.
Revenue (ttm)
$235.00K
Revenue Growth
-33.43%
P/S Ratio
n/a
Revenue / Employee
$3,615
Employees
65
Market Cap
457.48M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 235.00K | -118.00K | -33.43% |
Dec 31, 2023 | 353.00K | -10.03M | -96.60% |
Dec 31, 2022 | 10.39M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | 10.46M | 10.03M | 2,377.49% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ATYR News
- 19 hours ago - aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) - GlobeNewsWire
- 15 days ago - aTyr Pharma to Present at Upcoming Investor Conferences - GlobeNewsWire
- 16 days ago - aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference - GlobeNewsWire
- 19 days ago - aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 21 days ago - aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis - GlobeNewsWire
- 4 weeks ago - aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025 - GlobeNewsWire
- 2 months ago - aTyr Pharma to Participate in April Investor Conferences - GlobeNewsWire